JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory

benzinga.com/analyst-stock-ratings/price-target/25/06/45822460/jpmorgan-lifts-acadia-price-target-after-nuplazid-patent-victory

In May, the U.S. District Court for the District of Delaware ruled in favor of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) regarding its ‘721 formulation patent for Nuplazid (pimavanserin), Acadia’s drug for the treatment of Parkinson’s Disease Psychosis.
In order, the court ruled in favor…

This story appeared on benzinga.com, 2025-06-06 19:34:55.
The Entire Business World on a Single Page. Free to Use →